New drug combo tested for tough cancers

NCT ID NCT00600496

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researchers also studied how the drugs move through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6244 (also called ARRY-142886) combined with standard chemotherapies
What this could lead to: If successful, this could point toward a new combination treatment option for advanced solid tumors.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The combination may cause side effects or not work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colon carcinoma colonic neoplasm kidney cancer lung cancer lung neoplasm melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST NEOPLASMS COLON CANCER COLON NEOPLASMS COLONIC CANCER KIDNEY CANCER LUNG CANCER MELANOMA

Contacts and locations

Locations

Research Site

Detroit, Michigan, 48201, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.